Nilgun Tasdemir, PhD

Research Instructor

A430 Magee-Women's Research Institute, 204 Craft Avenue
Pittsburgh, PA 15213
Phone: 412-641-7736
Fax: 412-641-2468

Education

BS, Molecular Biology and Genetics, Bilkent University, Ankara, Turkey, 2006
MS, Molecular Biology and Genetics, Bilkent University, Ankara, Turkey, 2008
PhD, Biology, Watson School of Biological Sciences at Cold Spring Harbor Laboratory, NY, 2014
 
Nilgun Tasdemir, PhD
Invasive lobular breast carcinoma (ILC) is a unique and understudied histological subtype of breast cancer that accounts for 10-15% of all cases. As such, appropriate ILC-tailored research models are currently lacking and the genetic drivers of ILC still remain largely unknown. 

Dr. Tasdemir's research is focused on developing novel in vitro and in vivo models for studying ILC in the laboratory. She is currently utilizing these models to decipher mediators of ILC disease progression, as well as validating candidate genetic ILC drivers (such as the Cortical Actin Binding Protein CTTN) identified through profiling of human tumors. These studies should increase our understanding of ILC disease mechanisms and help uncover novel therapeutic targets to improve the clinical outcome of patients with this understudied subtype of breast cancer. 

 

Journal Articles

Bossart EA‡, Tasdemir N‡, Sikora MJ, Bahreini A, Levine KM, Chen J, Basudan A, Jacobsen BM, Burns TF, Oesterreich S. (2019). SNAIL is induced by Tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma. Breast Cancer Res Treat. doi: 10.1007/s10549-019-05161-8. [Epub ahead of print]. ( equal contributors).
 
Tasdemir N, Bossart EA, Li Z, Zhu L, Levine KM, Jacobsen BM, Tseng GC, Davidson NE, Oesterreich S. (2018). Comprehensive phenotypic characterization of human invasive lobular carcinoma cell lines in 2D and 3D cultures. Cancer Research. 8(21):6209-6222.
 
Banito A, Li X, Laport A, Roe JS, Sánchez-Vega F, Huang CH, Dancsok A, Hatzi A, Chen CC, Tschaharganeh DF, Tasdemir N, et al. (2018). The SS18-SSX oncoprotein hijacks KDM2B-PRC1.1 to drive synovial sarcoma. Cancer Cell. 33(3): 527-541.
 
Sakamaki J, Wilkinson S, Hahn M, Richter B, Tasdemir N, J O’Prey, et al. (2017). Bromodomain protein BRD4 is a transcriptional repressor of autophagy and lysosomal function. Molecular Cell. 66(4): 517-532.
 
Tasdemir N, Banito A, Roe JS, Alonso-Curbelo D, Camiolo M, Tschaharganeh DF, Huang CH, Aksoy O, Bolden JE, Chen CC, Fennell M, Thapar V, Chicas A, Vakoc CR, Lowe SW. (2016). BRD4 connects enhancer remodeling to senescence immune surveillance. Cancer Discovery. 6(6): 612-629.
 
Cheloufi S, Elling U, Hopfgartner B, Jung YL, Murn J, Ninova M, Hubmann M, Badeaux AI, Euong Ang C, Tenen D, Wesche DJ, Abazova N, Hogue M, Tasdemir N, et al. (2015). The histone chaperone CAF-1 safeguards somatic cell identity. Nature. 528: 218-224.
 
Bolden JE‡, Tasdemir N‡, Dow LE‡, van Es JH, Wilkinson JE, Zhao Z, Clevers H, Lowe SW. (2014). Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition. Cell Reports. 8(6): 1919-29. (equal contributors).